Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A nosographic and etiopathogenetic framework for subchondral bone marrow lesions in the knee: A narrative review.
J Exp Orthop
January 2025
Service of Orthopaedics and Traumatology, Department of Surgery EOC Lugano Switzerland.
Purpose: Subchondral bone marrow lesions (BMLs) are present in a wide range of pathologies with different prognoses. Thus, a careful diagnosis is mandatory to address them with the proper treatment. The aim of this review was to examine BMLs aetiology and their relationship with biomechanical and biological factors, to identify BMLs and help clinicians to properly recognize and treat each of these common alterations.
View Article and Find Full Text PDFImpact of procedural and patient-related risks on 1-year outcomes for patients treated with 1-month dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy after biodegradable-polymer drug-eluting stent implantation.
Cardiovasc Interv Ther
January 2025
Department of Internal Medicine, Division of Cardiology, Iwate Medical University, 2-1-1 Idaidori, Yahaba-Cho, Shiwa-Gun, Iwate, 028-3695, Japan.
In clinical practice, the impact of procedural or patient-related risk factors on 1-year clinical outcomes in patients receiving 1-month of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy after contemporary percutaneous coronary intervention (PCI) remains unclear. Using data from the multi-center REIWA registry which included patients treated with thin-strut biodegradable polymer drug-eluting stent (BP-DES) and 1-month DAPT followed by P2Y12 inhibitor monotherapy, we assessed the primary endpoint (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, ischemic or hemorrhagic stroke, and major or minor bleeding) in patients with and without procedural (treatment of three vessels, three or more lesions, three or more stents, bifurcation with two stents, long stenting, and target of chronic total occlusion) and patient-related risk factor (renal insufficiency, anemia, peripheral vascular disease, prior or current history of heart failure and advanced age of ≥ 75 years). Among the 1,202 patients who underwent complete revascularization by PCI, 276 (23.
View Article and Find Full Text PDFA Clinicopathologic and Molecular Reappraisal of Myxoinflammatory Fibroblastic Sarcoma-A Controversial and Pathologically Challenging Low-Grade Sarcoma.
Genes Chromosomes Cancer
January 2025
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Purpose: Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare, low-grade sarcoma affecting with predilection the acral soft tissues of middle-aged adults. Clinically, MIFS is associated with a high rate of local recurrence but infrequent distant metastases. The diagnosis remains challenging due to their wide histologic spectrum and overlap with reactive, benign, and low-grade malignant lesions.
View Article and Find Full Text PDF[Evidence for the extent and oncological benefit of lymphadenectomy for esophageal cancer].
Chirurgie (Heidelb)
January 2025
Klinik und Poliklinik für Allgemein‑, Viszeral‑, Thorax- und Transplantationschirurgie, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
The prognosis for esophageal cancer is determined in particular by the depth of infiltration (T stage) and lymph node metastasis (N status). In patients with locally advanced tumors, surgical resection is the current standard. The extent of the lymphadenectomy depends on the localization of the tumor, analogous to the choice of surgical technique.
View Article and Find Full Text PDFGut microbiota interact with breast cancer therapeutics to modulate efficacy.
EMBO Mol Med
January 2025
Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important factor in breast cancer etiology and treatment. Specifically, the impact of gut bacterial populations on breast cancer therapeutic outcomes is an emerging area of research. The microbiota's role in modifying the pharmacokinetics of chemotherapy and endocrine-targeting therapies can alter drug efficacy and toxicity profiles.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!